Literature DB >> 28959944

FDA approves first CAR T therapy.

Asher Mullard.   

Abstract

Year:  2017        PMID： 28959944     DOI： 10.1038/nrd.2017.196

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  33 in total

1.  Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma.

Authors:  Hakan Köksal; Pierre Dillard; Sarah E Josefsson; Solrun Melkorka Maggadottir; Sylvie Pollmann; Anne Fåne; Yngvild Nuvin Blaker; Klaus Beiske; Kanutte Huse; Arne Kolstad; Harald Holte; Gunnar Kvalheim; Erlend B Smeland; June H Myklebust; Else Marit Inderberg; Sébastien Wälchli
Journal:  Blood Adv       Date:  2019-04-23

2.  CRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapy.

Authors:  January Salas-Mckee; Weimin Kong; Whitney L Gladney; Julie K Jadlowsky; Gabriela Plesa; Megan M Davis; Joseph A Fraietta
Journal:  Hum Vaccin Immunother       Date:  2019-04-02       Impact factor: 3.452

Review 3.  Advancing biotechnology with CRISPR/Cas9: recent applications and patent landscape.

Authors:  Raphael Ferreira; Florian David; Jens Nielsen
Journal:  J Ind Microbiol Biotechnol       Date:  2018-01-24       Impact factor: 3.346

Review 4.  Nanomedicine and Onco-Immunotherapy: From the Bench to Bedside to Biomarkers.

Authors:  Vanessa Acebes-Fernández; Alicia Landeria-Viñuela; Pablo Juanes-Velasco; Angela-Patricia Hernández; Andrea Otazo-Perez; Raúl Manzano-Román; Rafael Gongora; Manuel Fuentes
Journal:  Nanomaterials (Basel)       Date:  2020-06-29       Impact factor: 5.076

5.  Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.

Authors:  Kevin A Hay; Jordan Gauthier; Alexandre V Hirayama; Jenna M Voutsinas; Qian Wu; Daniel Li; Ted A Gooley; Sindhu Cherian; Xueyan Chen; Barbara S Pender; Reed M Hawkins; Aesha Vakil; Rachel N Steinmetz; Gary Schoch; Aude G Chapuis; Brian G Till; Hans-Peter Kiem; Jorge D Ramos; Mazyar Shadman; Ryan D Cassaday; Utkarsh H Acharya; Stanley R Riddell; David G Maloney; Cameron J Turtle
Journal:  Blood       Date:  2019-02-06       Impact factor: 22.113

Review 6.  Therapeutic in vivo delivery of gene editing agents.

Authors:  Aditya Raguram; Samagya Banskota; David R Liu
Journal:  Cell       Date:  2022-07-06       Impact factor: 66.850

7.  Superkine IL-2 and IL-33 Armored CAR T Cells Reshape the Tumor Microenvironment and Reduce Growth of Multiple Solid Tumors.

Authors:  Shannon L Ferry; Courtney T Schiebout; Rachel A Brog; Cameron M Messier; W James Cook; Leena Abdullah; Jia Zou; Prathna Kumar; Charles L Sentman; H Robert Frost; Yina H Huang
Journal:  Cancer Immunol Res       Date:  2022-08-03       Impact factor: 12.020

Review 8.  Immune regulation of cardiac fibrosis post myocardial infarction.

Authors:  Yusra Zaidi; Eslie G Aguilar; Miguel Troncoso; Daria V Ilatovskaya; Kristine Y DeLeon-Pennell
Journal:  Cell Signal       Date:  2020-11-15       Impact factor: 4.850

Review 9.  Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Authors:  Ilana R Yurkiewicz; Lori Muffly; Michaela Liedtke
Journal:  Drug Des Devel Ther       Date:  2018-07-24       Impact factor: 4.162

10.  Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory.

Authors:  Sophie Viaud; Jennifer S Y Ma; Ian R Hardy; Eric N Hampton; Brent Benish; Lance Sherwood; Vanessa Nunez; Christopher J Ackerman; Elvira Khialeeva; Meredith Weglarz; Sung Chang Lee; Ashley K Woods; Travis S Young
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-29       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.